GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroOne Medical Technologies Corp (NAS:NMTC) » Definitions » Cash Ratio

NeuroOne Medical Technologies (NeuroOne Medical Technologies) Cash Ratio : 1.94 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is NeuroOne Medical Technologies Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. NeuroOne Medical Technologies's Cash Ratio for the quarter that ended in Dec. 2023 was 1.94.

NeuroOne Medical Technologies has a Cash Ratio of 1.94. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for NeuroOne Medical Technologies's Cash Ratio or its related term are showing as below:

NMTC' s Cash Ratio Range Over the Past 10 Years
Min: 0.01   Med: 1.08   Max: 15.89
Current: 1.94

During the past 13 years, NeuroOne Medical Technologies's highest Cash Ratio was 15.89. The lowest was 0.01. And the median was 1.08.

NMTC's Cash Ratio is ranked better than
61.75% of 855 companies
in the Medical Devices & Instruments industry
Industry Median: 1.23 vs NMTC: 1.94

NeuroOne Medical Technologies Cash Ratio Historical Data

The historical data trend for NeuroOne Medical Technologies's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroOne Medical Technologies Cash Ratio Chart

NeuroOne Medical Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 1.71 5.84 3.60 2.97

NeuroOne Medical Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.73 2.97 1.76 2.97 1.94

Competitive Comparison of NeuroOne Medical Technologies's Cash Ratio

For the Medical Devices subindustry, NeuroOne Medical Technologies's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroOne Medical Technologies's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's Cash Ratio distribution charts can be found below:

* The bar in red indicates where NeuroOne Medical Technologies's Cash Ratio falls into.



NeuroOne Medical Technologies Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

NeuroOne Medical Technologies's Cash Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash Ratio (A: Sep. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5.322/1.793
=2.97

NeuroOne Medical Technologies's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=2.681/1.383
=1.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuroOne Medical Technologies  (NAS:NMTC) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


NeuroOne Medical Technologies Cash Ratio Related Terms

Thank you for viewing the detailed overview of NeuroOne Medical Technologies's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroOne Medical Technologies (NeuroOne Medical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
7599 Anagram Dr., Eden Prairie, MN, USA, 55344
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Executives
Mark Christianson 10 percent owner, officer: VP, Business Dev and Marketing 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Ronald W. Mcclurg officer: Chief Financial Officer C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa director, officer: CEO and President 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Hijaz Haris officer: VP of Marketing C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
Morgan C. Frank 10 percent owner 2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907
Manchester Management Co Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02110
Manchester Explorer, L.p. 10 percent owner MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114
James E Besser 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Manchester Management Pr, Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Edward Andrle director C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344
Wade Fredrickson 10 percent owner 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Steve Mertens officer: Chief Technology Officer 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Scott Heuler officer: Vice President of Sales 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Paul Buckman director 12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Suraj Kalia director 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347